West to expand Irish site; Rexam to divest healthcare biz

By Dan Stanton

- Last updated on GMT

Devices on the move West expands Irish site whilst Rexam sells off pharma division
Devices on the move West expands Irish site whilst Rexam sells off pharma division
Having won a contract to make an injectable device for a large pharma firm West says it is expanding a facility in Ireland.

Tech Group Europe – a subsidiary of West Pharmaceutical Services – manufactures drug delivery and diagnostic devices from its facility in Dublin, Ireland and having secured a contract with what it describes as “a leading global pharmaceutical partner”​ is expanding the site by 12,000 sq ft.

“The expansion of our Dublin site will enable us to manufacture a progressive delivery system for accurate and safe administration of injectable diabetes medication,”​ Don O’Callaghan, VP and General Manager of Tech Group Europe told Outsourcing-Pharma.com.

Though he divulged neither the company nor the drug the device served, he did tell us “the device will be composed of the latest technology available in the field of injectable drug administration.”

The contract will see full scale production of the device begin in 2015 with the firm manufacturing the device before it gets shipped to the customer’s European filling site for final assembly.

Rexam to sell healthcare packaging business

In related news, fellow packaging and device manufacturer Rexam announced it was to sell its healthcare business to Montagu Private Equity for $805m (€590m) last week as part of its “long-term strategy to maximise shareholder value,” ​according to CEO Graham Chipchase.

The firm has manufactured the sub-sets of an insulin pen exclusively for Eli Lilly at a plant in La Verpilliere, France since 2008, and invested €15m in the site last year​ to cope with lilly’s growing demand.

When asked by this publication whether the sale of its healthcare business would have any effect on either Lilly or its existing pharma client base, spokesperson Laurence Quesdeville said it was business as usual.

“Our customers are aware, of course, of the proposed change,”​ she confirmed.

Related news

Show more

Related product


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers